Literature DB >> 22123375

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria.

Stephanie Korn1, Julia Both, Matthias Jung, Marisa Hübner, Christian Taube, Roland Buhl.   

Abstract

BACKGROUND: The goal of asthma treatment is to achieve and maintain current best control and reduce future risk of exacerbations and long-term morbidity.
OBJECTIVE: To prospectively compare current asthma control as defined by ACQ (asthma control questionnaire) and ACT (asthma control test) criteria with the GINA (Global Initiative for Asthma) classification in treated patients in a real-life setting.
METHODS: In 150 adult patients (48% male, age 46.3 ± 14.4 years., forced expiratory volume in 1 second [FEV(1)], 2.3 ± 0.9 L or 78.5 ± 21.8% pred.), asthma control was evaluated using the GINA classification as the "true" and ACQ-7, ACQ-5, and ACT as "predictor" criteria. The relationship between GINA-defined uncontrolled vs controlled/partly controlled asthma and ACQ and ACT scores was assessed with the ACQ cutpoint of ≥ 1.50 and the ACT cut-point of ≤ 19 for uncontrolled asthma.
RESULTS: The ACQ-7 and ACT correctly predicted GINA-defined uncontrolled asthma in 71.3% and 80.7% of patients, respectively. Sensitivity was high, with 88% for ACQ-7 and 94% for ACT, specificity was 57% and 70%, positive predictive value was 63% and 72%, and negative predictive value was 86% and 93%. Similar results were obtained using ACQ-5. ACQ-7 and ACT classified significantly more patients as having uncontrolled asthma compared with the GINA criteria (P < .001).
CONCLUSIONS: ACQ scores ≥ 1.50 and ACT scores ≤ 19 are suitable to indicate uncontrolled asthma. To identify GINA-defined uncontrolled asthma, cutoff points for ACQ-5 should be ≥ 1.9 and for ACT ≤ 16, at least in real-life adult patients with mostly moderate and severe asthma.
Copyright © 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123375     DOI: 10.1016/j.anai.2011.09.001

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  14 in total

1.  Cigarette smoke aggravates asthma by inducing memory-like type 3 innate lymphoid cells.

Authors:  Jongho Ham; Jihyun Kim; Kyoung-Hee Sohn; In-Won Park; Byoung-Whui Choi; Doo Hyun Chung; Sang-Heon Cho; Hye Ryun Kang; Jae-Woo Jung; Hye Young Kim
Journal:  Nat Commun       Date:  2022-07-04       Impact factor: 17.694

2.  Effect of nocturnal Temperature-controlled Laminar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis.

Authors:  A J Chauhan; T P Brown; W Storrar; L Bjermer; G Eriksson; F Radner; S Peterson; J O Warner
Journal:  Eur Clin Respir J       Date:  2021-03-10

3.  Depressive Symptoms and Overperception of Airflow Obstruction in Older Adults With Asthma.

Authors:  Jonathan M Feldman; Jacqueline Becker; Arushi Arora; Jesenya DeLeon; Tatiana Torres-Hernandez; Naomi Greenfield; Allyana Wiviott; Sunit Jariwala; Chang Shim; Alex D Federman; Juan P Wisnivesky
Journal:  Psychosom Med       Date:  2021-09-01       Impact factor: 3.864

Review 4.  Bronchial asthma: is personalized therapy on the horizon?

Authors:  Christian Taube
Journal:  Allergo J Int       Date:  2014-11-06

5.  Weekly self-measurement of FEV1 and PEF and its impact on ACQ (asthma control questionnaire)-scores: 12-week observational study with 76 patients.

Authors:  Christoph Ulrich Werner; Klaus Linde; Julia Schäffner; Constanze Storr; Antonius Schneider
Journal:  NPJ Prim Care Respir Med       Date:  2017-12-08       Impact factor: 2.871

6.  Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.

Authors:  Nora Drick; Benjamin Seeliger; Tobias Welte; Jan Fuge; Hendrik Suhling
Journal:  BMC Pulm Med       Date:  2018-07-18       Impact factor: 3.317

Review 7.  A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma.

Authors:  Vivian C Agumadu; Kamleshun Ramphul; Stephanie G Mejias; Ruhi Sonaye; Shaheen Sombans; Petras Lohana
Journal:  Cureus       Date:  2018-08-27

8.  Role of the pharmacist in improving inhaler technique and asthma management in rural areas in Jordan.

Authors:  Iman A Basheti; Yara B Salhi; Mariam M Basheti; Salim A Hamadi; Walid Al-Qerem
Journal:  Clin Pharmacol       Date:  2019-07-23

9.  Is there an association between postural balance and pulmonary function in adults with asthma?

Authors:  Vívian Pinto de Almeida; Fernando Silva Guimarães; Vanessa Joaquim Ribeiro Moço; Arthur de Sá Ferreira; Sara Lucia Silveira de Menezes; Agnaldo José Lopes
Journal:  Clinics (Sao Paulo)       Date:  2013-11       Impact factor: 2.365

10.  Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.

Authors:  Moritz Z Kayser; Nora Drick; Katrin Milger; Jan Fuge; Nikolaus Kneidinger; Stephanie Korn; Roland Buhl; Jürgen Behr; Tobias Welte; Hendrik Suhling
Journal:  J Asthma Allergy       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.